SEC Form DEFM14A filed by SpringWorks Therapeutics Inc.
$SWTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2024 | $60.00 | Outperform | Evercore ISI |
| 2/5/2024 | $75.00 | Buy | Guggenheim |
| 12/1/2022 | $45.00 | Buy | BofA Securities |
| 9/8/2021 | $97.00 → $105.00 | Overweight | JP Morgan |
| 8/5/2021 | $136.00 → $137.00 | Buy | HC Wainwright & Co. |